Down syndrome and Alzheimer's disease: common pathways, common goals

Inhibition and impulsivity: behavioral and neural basis of response control

Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921 · see citing works

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249 · see citing works

Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome

Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · see citing works

Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

Cataldo, A., Peterhoff, C., Troncoso, J., Gómez-Isla, T., Hyman, B., & Nixon, R. (2000) · American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 789 · see citing works

Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease

Rumble, B. A., Retallack, R. W., Hilbich, C., Simms, G., Multhaup, G., Martins, R. N., Hockey, A., Montgomery, P., Beyreuther, K. T., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 652 · see citing works

Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation

Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · see citing works

A Prospective Study of Alzheimer Disease in Down Syndrome

Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561 · see citing works

Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration

Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543 · see citing works

Cognitive deficits and associated neurological complications in individuals with Down's syndrome

Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484 · see citing works

Molecular mapping of alzheimer‐type dementia in Down's syndrome

Prasher, V. P., Farrer, M. J., Kessling, A. M., Fisher, E. M. C., West, R. J., Barber, P. C., & Butler, A. C. (1998) · Annals of Neurology · doi:10.1002/ana.410430316 · Cited by 414 · see citing works

The pathological association between down syndrome and Alzheimer disease

Mann, D. M. A. (1988) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(88)90041-3 · Cited by 346 · see citing works

Domains of genome-wide gene expression dysregulation in Down’s syndrome

Letourneau, A., Santoni, F. A., Bonilla, X., Sailani, M. R., Gonzalez, D., Kind, J., Chevalier, C., Thurman, R., Sandstrom, R. S., Hibaoui, Y., et al. (2014) · Nature · doi:10.1038/nature13200 · Cited by 319 · see citing works

Alzheimer’s-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition

Jiang, Y., Mullaney, K. A., Peterhoff, C. M., Che, S., Schmidt, S. D., Boyer‐Boiteau, A., Ginsberg, S. D., Cataldo, A. M., Mathews, P. M., & Nixon, R. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908953107 · Cited by 288 · see citing works

Alzheimer's disease in Down syndrome: Neurobiology and risk

Zigman, W. B., & Lott, I. T. (2007) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20163 · Cited by 279 · see citing works

Overexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome

Liu, F., Liang, Z., Wegiel, J., Hwang, Y., Iqbal, K., Grundke‐Iqbal, I., Ramakrishna, N., & Gong, C. (2008) · The FASEB Journal · doi:10.1096/fj.07-104539 · Cited by 272 · see citing works

Microarray Analysis of Hippocampal CA1 Neurons Implicates Early Endosomal Dysfunction During Alzheimer's Disease Progression

Ginsberg, S. D., Alldred, M. J., Counts, S., Cataldo, A. M., Neve, R. L., Jiang, Y., Wuu, J., Chao, M. V., Mufson, E. J., Nixon, R. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.030 · Cited by 257 · see citing works

Parallels of craniofacial maldevelopment in down syndrome and Ts65Dn mice

Richtsmeier, J. T., Baxter, L. L., & Reeves, R. H. (2000) · Developmental Dynamics · doi:10.1002/(sici)1097-0177(200002)217:2 · Cited by 255 · see citing works

A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions

Yu, T., Li, Z., Jia, Z., Clapcote, S. J., Liu, C., Li, S., Asrar, S., Pao, A., Chen, R., Fan, N., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq179 · Cited by 238 · see citing works

Age-Related Distribution of Neuropathologic Changes in the Cerebral Cortex of Patients With Down's Syndrome

Hof, P. R. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280065020 · Cited by 234 · see citing works

Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis

Wilcock, D. M., & Griffin, W. S. T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-84 · Cited by 230 · see citing works

Loss of Cholinergic Phenotype in Basal Forebrain Coincides with Cognitive Decline in a Mouse Model of Down's Syndrome

Granholm, A., Sanders, L., & Crnic, L. S. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7289 · Cited by 229 · see citing works

Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease

Ryoo, S., Cho, H., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y., Kim, M., Son, M., Seo, H., Chung, S., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05075.x · Cited by 227 · see citing works

Neurological phenotypes for Down syndrome across the life span

Lott, I. T. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00006-6 · Cited by 225 · see citing works

Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care

Trillo, L., Das, D., Hsieh, W., Medina, B., Moghadam, S., Lin, B., Dang, V., Sanchez, M. M., Miguel, Z. D., Ashford, J. W., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.008 · Cited by 224 · see citing works

Synaptic and cognitive abnormalities in mouse models of down syndrome: Exploring genotype‐phenotype relationships

Belichenko, P. V., Kleschevnikov, A. M., Salehi, A., Epstein, C. J., & Mobley, W. C. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21433 · Cited by 202 · see citing works

Oligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism

Berman, D. E., Dall'Armi, C., Voronov, S. V., McIntire, L. B. J., Zhang, H., Moore, A. Z., Staniszewski, A., Arancio, O., Kim, T.-W., & Di Paolo, G. (2008) · Nature Neuroscience · doi:10.1038/nn.2100 · Cited by 199 · see citing works

Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with down syndrome

Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.026 · Cited by 190 · see citing works

Selective cell death of hyperploid neurons in Alzheimer's disease.

Arendt, T., Brückner, M., Mosch, B., & Lösche, A. (2010) · American Journal of Pathology · doi:10.2353/ajpath.2010.090955 · Cited by 188 · see citing works

Promoter Mutations That Increase Amyloid Precursor-Protein Expression Are Associated with Alzheimer Disease

Theuns, J., Brouwers, N., Engelborghs, S., Sleegers, K., Bogaerts, V., Corsmit, E., Pooter, T. D., van Duijn, C. M., Deyn, P. P. D., & Broeckhoven, C. V. (2006) · The American Journal of Human Genetics · doi:10.1086/504044 · Cited by 187 · see citing works

Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease

Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187 · see citing works

Molecular characterization of the translocation breakpoints in the down syndrome mouse model Ts65Dn

Reinholdt, L. G., Ding, Y., Gilbert, G. T., Czechanski, A., Solzak, J. P., Roper, R. J., Johnson, M. T., Donahue, L. R., Lutz, C., & Davisson, M. T. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9357-z · Cited by 186 · see citing works

Development and validation of the Arizona Cognitive Test Battery for Down syndrome

Edgin, J. O., Mason, G. M., Allman, M. J., Capone, G. T., DeLeon, I. G., Maslen, C. L., Reeves, R. H., Sherman, S. L., & Nadel, L. (2010) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-010-9054-3 · Cited by 182 · see citing works

Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome

Voronov, S. V., Frere, S. G., Giovedi, S., Pollina, E. A., Borel, C., Zhang, H., Schmidt, C., Akeson, E. C., Wenk, M. R., Cimasoni, L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803756105 · Cited by 174 · see citing works

Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities

Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171 · see citing works

Induction of Toll-Like Receptor 9 Signaling as a Method for Ameliorating Alzheimer's Disease-Related Pathology

Scholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166 · see citing works

Down syndrome and Alzheimer's disease: A link between development and aging

Lott, I. T., & Head, E. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1025 · Cited by 157 · see citing works

Neuropathological Changes in Down's Syndrome Hippocampal Formation

Hyman, B. T. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280059019 · Cited by 147 · see citing works

Chromosome Missegregation and Trisomy 21 Mosaicism in Alzheimer's Disease

Geller, L. N., & Potter, H. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0236 · Cited by 146 · see citing works

Down Syndrome and Attention-Deficit/Hyperactivity Disorder (ADHD)

Ekstein, S., Glick, B., Weill, M., Kay, B., & Berger, I. (2011) · Journal of Child Neurology · doi:10.1177/0883073811405201 · Cited by 137 · see citing works

Life-long overexpression of S100β in Down’s syndrome: implications for Alzheimer pathogenesis

Griffin, W. S. T., Sheng, J. G., McKenzie, J. E., Royston, M. C., Gentleman, S., Brumback, R. A., Cork, L. C., Bigio, M. R. D., Roberts, G. W., & Mrak, R. E. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00074-8 · Cited by 134 · see citing works

Neuroanatomy of Down Syndrome in vivo: A Model of Preclinical Alzheimer’s Disease

Teipel, S. J., & Hampel, H. J. (2006) · Behavior Genetics · doi:10.1007/s10519-006-9047-x · Cited by 134 · see citing works

Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease–Like Transgenic Mouse Models

Frost, J. L., Le, K. X., Cynis, H., Ekpo, E., Kleinschmidt, M., Palmour, R. M., Ervin, F. R., Snigdha, S., Cotman, C. W., Saido, T. C., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.005 · Cited by 132 · see citing works

Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B

Handen, B. L., Cohen, A. D., Umapathy, C., Bulova, P. D., Cannon, S. A., Cohen, W. I., Mathis, C. A., Price, J. C., & Klunk, W. E. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.229 · Cited by 131 · see citing works

Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease

Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H., Siemers, E., Abushakra, S. R., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.004 · Cited by 124 · see citing works

Minocycline prevents cholinergic loss in a mouse model of Down's syndrome

Hunter, C. L., Bachman, D., & Granholm, A. (2004) · Annals of Neurology · doi:10.1002/ana.20250 · Cited by 120 · see citing works

Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions

Sturgeon, X., & Gardiner, K. J. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9321-y · Cited by 117 · cited 1× · see citing works

Altered DNA Methylation in Leukocytes with Trisomy 21

Kerkel, K., Schupf, N., Hatta, K., Pang, D. I., Salas, M. C., Kratz, A. F., Minden, M. D., Murty, V. V. V. S., Zigman, W. B., Mayeux, R. P., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001212 · Cited by 114 · see citing works

Aptamers and the RNA World, Past and PresentPreprint

Gold, L., Janjić, N., Jarvis, T. C., Schneider, D., Walker, J. J., Wilcox, S. K., & Zichi, D. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003582 · Cited by 114 · see citing works

Molecular basis of pharmacotherapies for cognition in Down syndrome

Gardiner, K. (2009) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.10.010 · Cited by 113 · see citing works

Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease

Wilcock, D. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/170276 · Cited by 104 · see citing works

Worldwide Alzheimer's Disease Neuroimaging Initiative

Carrillo, M. C., Bain, L. J., Frisoni, G. B., & Weiner, M. W. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.04.007 · Cited by 103 · see citing works

DYRK1A: a potential drug target for multiple down syndrome neuropathologies

Becker, W., Soppa, U., & Tejedor, F. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660186 · Cited by 103 · see citing works

Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A

Wu, Q., Liang, H., Shi, J., Jin, N., Grundke, I., Iqbal, K., Gong, C., & Liu, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr195 · Cited by 100 · see citing works

Trisomy for Synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes

Cossec, J., Lavaur, J., Berman, D. E., Rivals, I., Hoischen, A., Stora, S., Ripoll, C., Mircher, C., Grattau, Y., Olivo‐Marín, J., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds142 · Cited by 100 · see citing works

Chapter 4 Alzheimer's Disease in Adults with Down Syndrome

Zigman, W. B., Devenny, D. A., Krinsky‐McHale, S. J., Jenkins, E. C., Urv, T. K., Węgiel, J., Schupf, N., & Silverman, W. P. (2008) · International review of research in mental retardation · doi:10.1016/s0074-7750(08)00004-9 · Cited by 99 · see citing works

Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome

Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98 · see citing works

Aging and Down Syndrome

Head, E., Silverman, W. P., Patterson, D. W., & Lott, I. T. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/412536 · Cited by 94 · see citing works

Apolipoprotein E ε2 allele promotes longevity and protects patients with Downʼs syndrome from dementia

Royston, M. C., Mann, D. M. A., Pickering-Brown, S. M., Owen, F., Perry, R., Raghavan, R., Khin-IMu, C., Tyrer, S. P., Day, K. A., Crook, R., et al. (1994) · Neuroreport · doi:10.1097/00001756-199412000-00044 · Cited by 94 · see citing works

Onset of dementia is associated with apolipoprotein E ε4 in Down's syndrome

Schupf, N., Lee, J. H., Kapell, D., Zigman, W. B., Canto, B., Tycko, B., & Mayeux, R. P. (1996) · Annals of Neurology · doi:10.1002/ana.410400518 · Cited by 91 · see citing works

Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down Syndrome

Prasher, V. P., Sajith, S. G., Rees, S. D., Patel, A., Tewari, S., Schupf, N., & Zigman, W. B. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2039 · Cited by 89 · see citing works

Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade

Potter, H., & Wısnıewskı, T. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/489428 · Cited by 80 · see citing works

Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome

Schupf, N., Zigman, W. B., Tang, M. X., Pang, D. I., Mayeux, R. P., Mehta, P. D., & Silverman, W. P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb448b · Cited by 78 · see citing works

The proteins of human chromosome 21

Gardiner, K., & Costa, A. C. S. (2006) · American Journal of Medical Genetics. Part C, Seminars in Medical Genetics · doi:10.1002/ajmg.c.30098 · Cited by 74 · see citing works

Positron Emission Tomography of Brain β-Amyloid and Tau Levels in Adults With Down Syndrome

Nelson, L. D., Siddarth, P., Kepe, V., Scheibel, K. E., Huang, S. C., Barrio, J. R., & Small, G. W. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.104 · Cited by 72 · see citing works

Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility.

Landt, J., d’Abrera, J. C., Holland, A., Aigbirhio, F., Fryer, T., Canales, R., Hong, Y. T., Menon, D., Baron, J., & Zaman, S. H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.36 · Cited by 69 · see citing works

Age-Related Neurodegeneration and Memory Loss in Down Syndrome

Lockrow, J. P., Fortress, A. M., & Granholm, A. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/463909 · Cited by 64 · see citing works

Alzheimer Aβ disrupts the mitotic spindle and directly inhibits mitotic microtubule motors

Borysov, S. I., Granic, A., Padmanabhan, J., Walczak, C., & Potter, H. (2011) · Cell Cycle · doi:10.4161/cc.10.9.15478 · Cited by 63 · see citing works

Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age

Mann, D. M. A., Yates, P. O., Marcyniuk, B., & Ravindra, C. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90223-1 · Cited by 61 · see citing works

Positron Emission Tomography and Neuropathologic Estimates of Fibrillar Amyloid-β in a Patient With Down Syndrome and Alzheimer Disease

Sabbagh, M. N. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.535 · Cited by 52 · see citing works

Pathways to cognitive deficits in Down syndrome

Sturgeon, X., Le, T., Ahmed, M. M., & Gardiner, K. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00005-4 · Cited by 51 · see citing works

Down's syndrome and Alzheimer's disease: towards secondary prevention

Ness, S. L., Rafii, M. S., Aisen, P. S. S., Krams, M., Silverman, W. P., & Manji, H. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3822 · Cited by 50 · see citing works

A Noradrenergic Lesion Exacerbates Neurodegeneration in a Down Syndrome Mouse Model

Lockrow, J. P., Boger, H. A., Gerhardt, G. A., Aston‐Jones, G., Bachman, D., & Granholm, A. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101218 · Cited by 49 · see citing works

Dementia in Down’s syndrome: an MRI comparison with Alzheimer’s disease in the general population

Mullins, D., Daly, E., Simmons, A., Beacher, F. D. C. C., Foy, C. M. L., Lovestone, S., Hallahan, B. P., Murphy, K. C., & Murphy, D. (2013) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-5-19 · Cited by 48 · see citing works

Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease

Lv, H., Jia, L., & Jia, J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.001 · Cited by 43 · see citing works

Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain

Ahmed, M. M., Dhanasekaran, A. R., Tong, S., Wiseman, F. K., Fisher, E., Tybulewicz, V. L. J., & Gardiner, K. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt017 · Cited by 42 · see citing works

Discoveries in Down syndrome

Kleschevnikov, A. M., Belichenko, P. V., Salehi, A., & Wu, C. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00010-8 · Cited by 29 · see citing works

Rescue of Synaptic Failure and Alleviation of Learning and Memory Impairments in a Trisomic Mouse Model of Down Syndrome

Blanchard, J., Bolognin, S., Chohan, M. O., Rabe, A., Iqbal, K., & Grundke, I. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318236e9ad · Cited by 28 · see citing works

Mild cognitive impairment identified in older individuals with down syndrome by reduced telomere signal numbers and shorter telomeres measured in microns

Jenkins, E. C., Ye, L., Velinov, M. T., Krinsky‐McHale, S. J., Zigman, W. B., Schupf, N., & Silverman, W. P. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32066 · Cited by 23 · see citing works

The Amyloid-β Pathway in Alzheimer’s Disease

Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · see citing works

Alzheimer's disease: experimental models and reality

Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810 · see citing works

Alzheimer's disease

López, J. A., González, H. M., & Léger, G. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 834 · see citing works

Dementia in Down syndrome: unique insights for Alzheimer disease research

Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383 · see citing works

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials

Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Morris, J. C., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 314 · see citing works

Aducanumab: Appropriate Use Recommendations

Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.41 · Cited by 316 · see citing works

Dishing out mini-brains: Current progress and future prospects in brain organoid research

Kelava, I., & Lancaster, M. A. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.06.037 · Cited by 309 · see citing works

Down syndrome and the complexity of genome dosage imbalance

Antonarakis, S. (2016) · Nature reviews genetics · doi:10.1038/nrg.2016.154 · Cited by 264 · see citing works

Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies

Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 290 · see citing works

Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology

Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289 · see citing works

Immunotherapeutic Approaches for Alzheimer’s Disease

Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · see citing works

The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis

Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275 · see citing works

Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination

Olmos-Serrano, J. L., Kang, H. J., Tyler, W. A., Silbereis, J. C., Cheng, F., Zhu, Y., Pletikos, M., Jankovic-Rapan, L., Cramer, N. P., Galdzicki, Z., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.042 · Cited by 239 · see citing works

Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity

Araya, P., Waugh, K. A., Sullivan, K. D., Núñez, N. G., Roselli, E., Smith, K. P., Granrath, R. E., Rachubinski, A. L., Enriquez Estrada, B., Butcher, E. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908129116 · Cited by 179 · see citing works

Early and Late CNS Inflammation in Alzheimer’s Disease: Two Extremes of a Continuum?

Cuello, A. C. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.005 · Cited by 164 · see citing works

Alzheimer Disease and Its Growing Epidemic

Hickman, R. A., Faustin, A., & Wısnıewskı, T. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.009 · Cited by 156 · see citing works

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 156 · see citing works

Outcome Measures for Clinical Trials in Down Syndrome

Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., d'Ardhuy, X. L., Capone, G., Conners, F. A., Mervis, C. B., Abbeduto, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.247 · Cited by 153 · see citing works

Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome

Waugh, K. A., Araya, P., Pandey, A., Jordan, K. R., Smith, K. P., Granrath, R. E., Khanal, S., Butcher, E. T., Estrada, B. E., Rachubinski, A. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.038 · Cited by 150 · see citing works

Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview

Varesi, A., Carrara, A., Pires, V. G., Floris, V., Pierella, E., Savioli, G., Prasad, S., Esposito, C., Ricevuti, G., Chirumbolo, S., et al. (2022) · Cells · doi:10.3390/cells11081367 · Cited by 142 · see citing works

Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors

Powers, R. K., Culp‐Hill, R., Ludwig, M. P., Smith, K. P., Waugh, K. A., Minter, R., Tuttle, K. D., Lewis, H. C., Rachubinski, A. L., Granrath, R. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12739-9 · Cited by 139 · see citing works

Medical vulnerability of individuals with Down syndrome to severe COVID-19–data from the Trisomy 21 Research Society and the UK ISARIC4C survey

Hüls, A., Costa, A. C. S., Dierssen, M., Baksh, R. A., Bargagna, S., Baumer, N., Brandão, A. C., Carfì, A., Carmona‐Iragui, M., Chicoine, B. A., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100769 · Cited by 134 · see citing works

Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome

Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129 · see citing works

APOE-amyloid interaction: Therapeutic targets

Wısnıewskı, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 125 · see citing works

The implications of exosomes in pregnancy: emerging as new diagnostic markers and therapeutics targets

Ghafourian, M., Mahdavi, R., Jonoush, Z. A., Sadeghi, M., Ghadiri, N., Farzaneh, M., & Salehi, A. M. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00853-z · Cited by 128 · see citing works

mTOR hyperactivation in Down Syndrome underlies deficits in autophagy induction, autophagosome formation, and mitophagy

Bordi, M., Darji, S., Sato, Y., Mellén, M., Berg, M. J., Kumar, A., Jiang, Y., & Nixon, R. A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1752-5 · Cited by 124 · see citing works

The prevalence and incidence of early‐onset dementia among adults with autism spectrum disorder

Vivanti, G., Tao, S., Lyall, K., Robins, D. L., & Shea, L. (2021) · Autism Research · doi:10.1002/aur.2590 · Cited by 124 · see citing works

Contributions of DNA Damage to Alzheimer’s Disease

Lin, X., Kapoor, A., Gu, Y., Chow, M. J., Peng, J., Zhao, K., & Tang, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051666 · Cited by 117 · see citing works

The Early Presentation of Dementia in People with Down Syndrome: a Systematic Review of Longitudinal Studies

Lautarescu, A., Holland, A. J., & Zaman, S. H. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9341-9 · Cited by 115 · see citing works

Cerebrovascular pathology in Down syndrome and Alzheimer disease

Head, E., Phelan, M. J., Doran, E., Kim, R. C., Poon, W. W., Schmitt, F. A., & Lott, I. T. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0499-4 · Cited by 105 · see citing works

Further understanding the connection between Alzheimer's disease and Down syndrome

Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105 · see citing works

Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions

Dierssen, M., Fructuoso, M., de Lagrán, M. M., Marzia Perluigi, A., & Barone, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00670 · Cited by 101 · see citing works

Immunotherapy for Alzheimer's disease

Wısnıewskı, T., & Goñi, F. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.020 · Cited by 99 · see citing works

Alzheimer's Disease in the Down Syndrome: An Overview of Genetics and Molecular Aspects

Gomes, F. D. C., Mattos, M. F., Goloni‐Bertollo, E. M., & Pavarino, É. C. (2021) · Neurology India · doi:10.4103/0028-3886.310062 · Cited by 102 · see citing works

Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis

Zhang, Y., Che, M., Yuan, J., Yu, Y., Cao, C., Qin, X.-Y., & Cheng, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21060 · Cited by 98 · see citing works

Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer’s Disease Pathogenesis

Garbuz, D. G., Zatsepina, O. G., & Evgen’ev, M. B. (2021) · Molecular Biology · doi:10.1134/s002689332104004x · Cited by 95 · see citing works

Changes in cognitive function after a 12-week exercise intervention in adults with Down syndrome

Ptomey, L. T., Szabo‐Reed, A. N., Willis, E. A., Gorczyca, A. M., Greene, J. L., Danon, J. C., & Donnelly, J. E. (2018) · Disability and health journal · doi:10.1016/j.dhjo.2018.02.003 · Cited by 93 · see citing works

Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein

Gómez, W., Morales, R., Maracaja‐Coutinho, V., Parra, V., & Nassif, M. (2020) · Aging · doi:10.18632/aging.102677 · Cited by 87 · see citing works

Internal m7G methylation: A novel epitranscriptomic contributor in brain development and diseases

Xia, X., Wang, Y., & Zheng, J. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.003 · Cited by 87 · see citing works

Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders

Batarseh, Y. S., Duong, Q.-V., Mousa, Y. M., Rihani, S. B. A., Elfakhri, K. H., & Kaddoumi, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030338 · Cited by 80 · see citing works

Exosomal biomarkers in Down syndrome and Alzheimer's disease

Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.028 · Cited by 78 · see citing works

β2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function

Gao, Y., Hong, Y., Huang, L., Zheng, S., Zhang, H., Wang, S., Yao, Y., Zhao, Y., Zhu, L., Xu, Q., et al. (2023) · Cell · doi:10.1016/j.cell.2023.01.021 · Cited by 75 · see citing works

Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease

Strupp, B. J., Powers, B. E., Velázquez, R., Ash, J. A., Kelley, C. M., Alldred, M. J., Strawderman, M. S., Caudill, M. A., Mufson, E. J., & Ginsberg, S. D. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921100311 · Cited by 71 · see citing works

Editorial (Thematic Issue: The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective)

Salehi, A., Ashford, J. W., & Mufson, E. J. (2015) · Current Alzheimer Research · doi:10.2174/1567205012999151021102914 · Cited by 72 · see citing works

JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome

Tuttle, K. D., Waugh, K. A., Araya, P., Minter, R., Orlicky, D. J., Ludwig, M., Andrysik, Z., Burchill, M. A., Tamburini, B. A. J., Sempeck, C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108407 · Cited by 72 · see citing works

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study

Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E. W., Christian, B. T., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00139-3 · Cited by 70 · see citing works

Aging with Down Syndrome—Where Are We Now and Where Are We Going?

Alldred, M. J., Martini, A. C., Patterson, D., Hendrix, J. A., & Granholm, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204687 · Cited by 70 · see citing works

Nanomedicine-based immunotherapy for central nervous system disorders

Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 68 · see citing works

Trans-Acting Epigenetic Effects of Chromosomal Aneuploidies: Lessons From Down Syndrome and Mouse Models

Do, C., Xing, Z., Yu, Y. E., & Tycko, B. (2016) · Epigenomics · doi:10.2217/epi-2016-0138 · Cited by 65 · see citing works

Distribution of microglial phenotypes as a function of age and Alzheimer's disease neuropathology in the brains of people with Down syndrome

Martini, A. C., Helman, A. M., McCarty, K. L., Lott, I. T., Doran, E., Schmitt, F. A., & Head, E. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12113 · Cited by 66 · see citing works

Insights into the Potential Role of Mercury in Alzheimer’s Disease

Bjørklund, G., Tinkov, A. A., Dadar, M., Rahman, M. M., Chirumbolo, S., Skalny, A. V., Геннадиевна, С. М., Haley, B. E., Ajsuvakova, O. P., & Aaseth, J. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01274-3 · Cited by 64 · see citing works

Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance

Rhaman, M. M., Islam, M. R., Akash, S., Mim, M., Noor alam, M., Nepovimova, E., Valis, M., Kuca, K., & Sharma, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.989471 · Cited by 63 · see citing works

Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence

Chung, H., Green, P. H. R., Wang, T. C., & Kong, X. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s280953 · Cited by 59 · see citing works

Perinatal Choline Supplementation Reduces Amyloidosis and Increases Choline Acetyltransferase Expression in the Hippocampus of the APPswePS1dE9 Alzheimer's Disease Model Mice

Mellott, T. J., Huleatt, O. M., Shade, B. N., Pender, S. M., Liu, Y. B., Slack, B. E., & Blusztajn, J. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170450 · Cited by 53 · see citing works

A neuronal blood marker is associated with mortality in old age

Kaeser, S. A., Lehallier, B., Thinggaard, M., Häsler, L. M., Apel, A., Bergmann, C., Berdnik, D., Jeune, B., Christensen, K., Grönke, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00028-4 · Cited by 57 · see citing works

Neurogenetic disorders across the lifespan: from aberrant development to degeneration

Hickman, R. A., O’Shea, S. A., Mehler, M. F., & Chung, W. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00595-5 · Cited by 55 · see citing works

Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease

Potter, H., Granic, A., & Caneus, J. (2015) · Current Alzheimer Research · doi:10.2174/156720501301151207100616 · Cited by 53 · see citing works

Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative and Neurodevelopmental Disorders

Potter, H., Chial, H. J., Caneus, J., Elos, M. T., Elder, N., Borysov, S. I., & Granic, A. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01092 · Cited by 52 · see citing works

Mitochondria break free: Mitochondria-derived vesicles in aging and associated conditions

Ferrucci, L., Guerra, F., Bucci, C., Marzetti, E., & Picca, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102549 · Cited by 52 · see citing works

CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer’s disease

Mendióroz, M., Celarain, N., Altuna, M., de Gordoa, J. S., Zelaya, M. V., Roldán, M., Rubio, I., Larumbe, R., Erro, M. E., Méndez-López, I., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0183-0 · Cited by 51 · see citing works

Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome

Hamlett, E. D., Boger, H. A., Ledreux, A., Kelley, C. M., Mufson, E. J., Falangola, M. F., Guilfoyle, D. N., Nixon, R. A., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 51 · see citing works

Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine

Zhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49 · see citing works

Enhancing teaching and learning in STEM Labs: The development of an android-based virtual reality platform

Laseinde, O. T., & Dada, D. (2023) · Materials Today Proceedings · doi:10.1016/j.matpr.2023.09.020 · Cited by 48 · see citing works

An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome

Belichenko, P., Madani, R., Rey-Bellet, L., Pihlgren, M., Becker, A., Plassard, A., Vuillermot, S., Giriens, V., Nosheny, R., Kleschevnikov, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152471 · Cited by 35 · see citing works

Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer’s Disease

Helman, A. M., Siever, M., McCarty, K. L., Lott, I. T., Doran, E. W., Abner, E. L., Schmitt, F. A., & Head, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180589 · Cited by 49 · see citing works

Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies

Langerscheidt, F., Wied, T., Kabbani, M. A. A., van Eimeren, T., Wunderlich, G., & Zempel, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12314-3 · Cited by 45 · see citing works

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome

Kamer, A. R., Fortea, J., Videla, S., Mayoral, A., Janal, M. N., Carmona‐Iragui, M., Benejam, B., Craig, R. G., Saxena, D. B., Corby, P. M. A., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.01.001 · Cited by 44 · see citing works

Recent advancements toward therapeutic vaccines against Alzheimer’s disease

Herline, K., Drummond, E., & Wısnıewskı, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 44 · see citing works

Prevalence of dementia in people with intellectual disabilities: Cross‐sectional study

Takenoshita, S., Terada, S., Kuwano, R., Inoue, T., Cyoju, A., Suemitsu, S., & Yamada, N. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5258 · Cited by 43 · see citing works

Dissecting Alzheimer disease in Down syndrome using mouse models

Choong, X. Y., Tosh, J., Pulford, L. J., & Fisher, E. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 40 · see citing works

Longitudinal measures of cognition in the Ts65Dn mouse: Refining windows and defining modalities for therapeutic intervention in Down syndrome

Olmos-Serrano, J. L., Tyler, W. A., Cabral, H., & Haydar, T. F. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.005 · Cited by 42 · see citing works

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease

Nyberg, L. H., Lundquist, A., Adolfsson, A. N., Andersson, M., Zetterberg, H., Blennow, K., & Adolfsson, R. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12050 · Cited by 42 · see citing works

Neuropsychological and neurophysiological characterization of mild cognitive impairment and Alzheimer's disease in Down syndrome

García-Alba, J., Ramírez‐Toraño, F., Esteba‐Castillo, S., Bruña, R., Moldenhauer, F., Novell, R., Romero-Medina, V., Maestú, F., & Fernández, A. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.07.017 · Cited by 41 · see citing works

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome

Dekker, A. D., Fortea, J., Blesa, R., & Deyn, P. P. D. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.02.006 · Cited by 41 · see citing works

The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease

Rujeedawa, T., Félez, E. C., Clare, I. C. H., Fortea, J., Strydom, A., Rebillat, A., Coppus, A. M. W., Levin, J., & Zaman, S. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194582 · Cited by 40 · see citing works

Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer’s disease and not in other tauopathies

Pires, G., McElligott, S., Drusinsky, S., Halliday, G. M., Potier, M., Wısnıewskı, T., & Drummond, E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0848-6 · Cited by 39 · see citing works

Mechanistic insights into the role of herpes simplex virus 1 in Alzheimer’s disease

Feng, S., Liu, Y., Zhou, Y., Shu, Z., Cheng, Z., Brenner, C., & Feng, P. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1245904 · Cited by 36 · see citing works

Down syndrome and microRNAs (Review)

s, A. B. ⁄., Rodrigues, A., Gomes, B. C., & Rueff, J. (2017) · Biomedical Reports · doi:10.3892/br.2017.1019 · Cited by 36 · see citing works

Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules

Lanzillotta, C., & Domenico, F. D. (2021) · Biomolecules · doi:10.3390/biom11020266 · Cited by 35 · see citing works

Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer’s Disease

Alldred, M. J., Penikalapati, S. C., Lee, S. H., Heguy, A., Roussos, P., & Ginsberg, S. D. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02453-3 · Cited by 36 · see citing works

Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease

Tentolouris-Piperas, V., Ryan, N. S., Thomas, D. L., & Kinnunen, K. M. (2016) · Brain Research · doi:10.1016/j.brainres.2016.11.011 · Cited by 36 · see citing works

CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation

Alldred, M. J., Chao, H. M., Lee, S. H., Beilin, J., Powers, B. E., Petkova, E., Strupp, B. J., & Ginsberg, S. D. (2018) · Hippocampus · doi:10.1002/hipo.22832 · Cited by 35 · see citing works

Developmental deficits and staging of dynamics of age associated Alzheimer’s disease neurodegeneration and neuronal loss in subjects with Down syndrome

Wegiel, J., Flory, M., Kuchna, I., Nowicki, K., Wegiel, J., Ma, S. Y., Zhong, N., Bobrowicz, T., de Leon, M. D., Lai, F., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01300-9 · Cited by 27 · see citing works

Oxidative Phosphorylation Is Dysregulated Within the Basocortical Circuit in a 6-month old Mouse Model of Down Syndrome and Alzheimer’s Disease

Alldred, M. J., Lee, S. H., Stutzmann, G. E., & Ginsberg, S. D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.707950 · Cited by 34 · see citing works

Additional mechanisms conferring genetic susceptibility to Alzheimer’s disease

Calero, M., Gómez‐Ramos, A., Calero, O., Soriano, E., Ávila, J., & Medina, M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00138 · Cited by 33 · see citing works

Informant-based assessment instruments for dementia in people with intellectual disability: A systematic review and standardised evaluation

Zeilinger, E. L., Novaković, I. Z., Komenda-Schned, S., Franken, F., Sobisch, M., Mayer, A., Neumann, L. C., Loosli, S. V., Hoare, S., & Pietschnig, J. (2021) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2021.104148 · Cited by 32 · see citing works

Nanomedicine-based immunotherapy for Alzheimer's disease

Hoque, M., Samanta, A., Alam, S. S. M., Zughaibi, T. A., Kamal, M. A., & Tabrez, S. S. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104973 · Cited by 31 · see citing works

Mouse-based genetic modeling and analysis of Down syndrome

Xing, Z., Li, Y., Pao, A., Bennett, A. S., Tycko, B., Mobley, W. C., & Yu, Y. E. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw040 · Cited by 30 · see citing works

Aging With Down Syndrome: The Dual Diagnosis: Alzheimer’s Disease and Down Syndrome

Cipriani, G., Danti, S., Carlesi, C., & Fiorino, M. D. (2018) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317518761093 · Cited by 30 · see citing works

Long‐term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease

Alldred, M. J., Chao, H. M., Lee, S. H., Beilin, J., Powers, B. E., Petkova, E., Strupp, B. J., & Ginsberg, S. D. (2019) · The FASEB Journal · doi:10.1096/fj.201802669rr · Cited by 29 · see citing works

Mitochondria Have Made a Long Evolutionary Path from Ancient Bacteria Immigrants within Eukaryotic Cells to Essential Cellular Hosts and Key Players in Human Health and Disease

Atlante, A., & Valenti, D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45050283 · Cited by 30 · see citing works

Novel method for collecting hippocampal interstitial fluid extracellular vesicles (EV ISF ) reveals sex‐dependent changes in microglial EV proteome in response to Aβ pathology

Pait, M. C., Kaye, S. D., Su, Y., Kumar, A., Singh, S., Gironda, S. C., Vincent, S., Anwar, M., Carroll, C. M., Snipes, J. A., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12398 · Cited by 27 · see citing works

Cholinergic neurodegeneration in Alzheimer disease mouse models

Shekari, A., & Fahnestock, M. L. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00013-7 · Cited by 27 · see citing works

Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome

Kazim, S. F., Blanchard, J., Bianchi, R., & Iqbal, K. (2017) · Scientific Reports · doi:10.1038/srep45561 · Cited by 28 · see citing works

The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice

Ahmed, M. M., Wang, A. C., Elos, M. T., Chial, H. J., Sillau, S., Solano, D. A., Coughlan, C. M., Aghili, L., Anton, P. E., Markham, N. E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105694 · Cited by 30 · see citing works

Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues

London, J., Rouch, C., Bui, L. C., Assayag, E., Souchet, B., Daubigney, F., Medjaoui, H., Luquet, S. H., Magnan, C., Delabar, J. M., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0591-6 · Cited by 27 · see citing works

Plasma Neurofilament Light and Alzheimer’s Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)

Rafii, M. S., Donohue, M., Matthews, D. C., Muranevici, G., Ness, S. L., O’Bryant, S. E., & Rissman, R. A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190322 · Cited by 26 · see citing works

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue

Lemoine, L., Ledreux, A., Mufson, E. J., Perez, S. E., Šimić, G., Doran, E. W., Lott, I. T., Carroll, S. L., Bharani, K., Thomas, S., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00414-3 · Cited by 26 · see citing works

Preventing Alzheimer’s: Our Most Urgent Health Care Priority

Sherzai, D., & Sherzai, A. Z. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827619843465 · Cited by 26 · see citing works

Maternal Choline Supplementation as a Potential Therapy for Down Syndrome: Assessment of Effects Throughout the Lifespan

Powers, B. E., Velázquez, R., Strawderman, M. S., Ginsberg, S. D., Mufson, E. J., & Strupp, B. J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.723046 · Cited by 25 · see citing works

Further understanding the connection between Alzheimer's disease and Down syndrome

Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105 · see citing works

Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology

Rafii, M. S., Schlachetzki, Z., Barroeta, I., Head, E., Fortea, J., & Ances, B. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00237-6 · Cited by 44 · see citing works

Down's syndrome and Alzheimer's disease

Mann, D. M. A. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511526886.011 · Cited by 2 · see citing works

Relationship of Down’s Syndrome to Alzheimer’s Disease

Rabe, A., Wisniewski, K. E., Schupf, N., & Wı́sniewski, H. M. (1990) · Springer eBooks · doi:10.1007/978-1-4613-0525-5_21 · Cited by 19 · see citing works

Alzheimer’s disease and Down syndrome

Pelt, K. L. V., Head, E., Schmitt, F. A., & Koehl, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00020-9 · Cited by 5 · see citing works